Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Cardiovascular Diseases, Hypertension
Interventions: Williams LifeSkills Stress and Anger Management Workshop, High school classes; Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 14 Years to 18 Years
Enrollment: 259 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Augusta, Georgia • Durham, North Carolina

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 12 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension, Chronic Kidney Disease
Interventions: DASH Diet, Control Diet; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension, Cardiovascular Disease
Interventions: Home Blood Pressure Monitor Group; Other
Lead sponsor: New York City Department of Health and Mental Hygiene; Government
Eligibility: 18 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York • The Bronx, New York

Conditions: Hypertension, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Comorbidities and Coexisting Conditions
Interventions: Improved Community Health Volunteer (CHV) program; Other
Lead sponsor: International Rescue Committee; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: amlodipine besylate/benazepril hydrochloride; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 259 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Family Relations
Interventions: Walk Together; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Valsartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more

Conditions: Hypertension, Pre-Hypertension
Interventions: Isometric Handgrip Training, Aerobic Exercise Training; Other
Lead sponsor: University Institute of Maia; Other
Eligibility: 65 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more

Conditions: Hypertension, Medication Adherence
Interventions: Medication Reminder App; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glaucoma
Interventions: Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Newport Beach, California • Largo, Florida • Miami, Florida + 7 more

Conditions: Hypertension, Vitamin D Deficiency
Interventions: calcitriol, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 55 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cardiovascular Diseases, Hypertension, Racism, Vascular Diseases
Interventions: MitoQ; Dietary Supplement
Lead sponsor: Auburn University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more

Conditions: Hypertension
Interventions: Favor one of two thiazides for new prescriptions & attempt target dose; Other
Lead sponsor: VA Pharmacy Benefits Management Strategic Healthcare Group; Federal
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Hines, Illinois • Asheville, North Carolina • Wilkes-Barre, Pennsylvania + 2 more

Conditions: Heart Failure
Interventions: Performance of WHEELS-I in promoting DASH/SRD adoption; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension
Interventions: Geneticure for RDN Genetic Panel; Genetic
Lead sponsor: Geneticure, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Preeclampsia
Interventions: Women w/ Preeclampsia w/o Visual Disturbances or Headache, Women w/ Preeclampsia w/ Visual Disturbances or Headaches, Women w/o Preeclampsia; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 20 Years to 65 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertensive Heart Disease, Hypertension
Interventions: More intensive CHW Intervention, Less Intensive CHW Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 25 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Preeclampsia, Gestational Hypertension
Interventions: spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Salt; Excess, Hypertension
Interventions: No Salt, No β-OHB, High Salt, No β-OHB, High Salt, High β-OHB; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 19 Years to 39 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Artesia, California • Los Angeles, California • San Diego, California + 3 more

Search by objective public record fields.

Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study

Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices

Community Models for Hypertension and Diabetes Care for Refugees

Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

Walk Together: A Family-Based Intervention for Hypertension In African Americans

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

The Hypotensive Effects of Home-Based Isometric Handgrip Training in Older Adults With Pre-Hypertension and Hypertension - The HoldAge Trial

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Pill Bottle vs Reminder App

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Effects of Vitamin D on Renin Expression in Hypertensive Patients

Mitochondria Oxidative Stress and Vascular Health Study

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

Novel Biomarkers of Preeclampsia, Aquaporin, Fatty Acid, and S110B

Asian American Partnerships in Research and Empowerment (AsPIRE)

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Ketone Ester and Salt (KEAS) in Young Adults

Prevalence of Ocular Surface Disease in Glaucoma Patients

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma